Markers of blood-brain barrier disruption increase early and persistently in COVID-19 patients with neurological manifestations.
Bonetto V, Pasetto L, Lisi I, Carbonara M, Zangari R, Ferrari E, Punzi V, Luotti S, Bottino N, Biagianti B, Moglia C, Fuda G, Gualtierotti R, Blasi F, Canetta C, Montano N, Tettamanti M, Camera G, Grimoldi M, Negro G, Rifino N, Calvo A, Brambilla P, Biroli F, Bandera A, Nobili A, Stocchetti N, Sessa M, Zanier ER.
Bonetto V, et al. Among authors: ferrari e.
Front Immunol. 2022 Dec 15;13:1070379. doi: 10.3389/fimmu.2022.1070379. eCollection 2022.
Front Immunol. 2022.
PMID: 36591311
Free PMC article.
On the contrary, MMP-9 was higher at acute phase in NeuroCovid patients, with a severity dependency in the long-term. We also found a clear severity dependency of NFL and GFAP levels, with deceased patients showing the highest levels. ...Our observations may provide hints …
On the contrary, MMP-9 was higher at acute phase in NeuroCovid patients, with a severity dependency in the long-term. We also found a …